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Abstract 
Background: The relative diagnostic accuracy of interferon gamma release assays (IGRAs; 
QuantiFERON®-TB Gold In-Tube [QFT] and T-SPOT®.TB) and the tuberculin skin test (TST) for 
latent tuberculosis (TB) infection in people with end stage kidney disease (ESKD) is uncertain and 
national guidelines for their use are inconsistent.  
Study design: Systematic review.  
Selection criteria for studies: Evaluated performance of tests for latent TB with clinical risk factor 
assessment. 
Setting and population: People with ESKD (chronic kidney disease stage five [eGFR < 30] or 
kidney transplant recipients). No limits on setting. 
Index tests: QFT, TSPOT.TB, TST, MycoDot, Determiner TBGL Antibody and flow cytometry.  
Outcomes: Odds of test positivity with clinical risk factor for latent TB, expressed as Odds Ratios 
(OR, with CI 95%). Relative Odds Ratios (ROR, with CI 95%). 
Results: Forty-seven studies (6828 participants) were included, but only 30 studies (4546 
participants) contained sufficient data to contribute to meta-analysis. Studies were predominately in 
the dialysis population (23/30, 3700 participants) in countries with low to high TB prevalence (4.7-
258.0 cases/105 persons). BCG vaccination rate was variable (2.7-100.0%). Nine studies compared 
IGRAs with the TST directly, 17 studies evaluated the TST only, and the remaining four studies 
evaluated other tests. Compared to a positive TST, a positive QFT was more strongly associated 
with radiological evidence of past TB (ROR 4.29, CI95% 1.83-10.3, p=0.001), and contact with 
active TB (ROR 3.36, 95%CI 1.61-7.01, p=0.001). Compared to a negative TST, a negative QFT 
was more strongly associated with BCG vaccination (ROR 0.30, 95%CI 0.14-0.63, p=0.002). There 
was insufficient data to compare performance of the TSPOT.TB with the TST or QFT.  
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Limitations: Seventeen of 47 included studies (36.2%) did not contain sufficient data to contribute 
to meta-analysis.  
Conclusion: Compared to the TST, the QFT assay was more strongly associated with risk factors 
for latent TB in ESKD. 
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Introduction  
Uraemia in end stage kidney disease (ESKD) contributes to generalised immune dysfunction which 
results in increased susceptibility to infectious diseases, including tuberculosis1,2. Individuals with 
ESKD are up to 50 times more likely to develop active TB than the general population and 
mortality is high, between 17 and 75%3. A recent study in Australia reported an incidence of active 
TB in people on dialysis of 66.8 per 100000 persons/ year and an adjusted relative risk of 7.87 when 
compared with the general population4. Accurate and timely diagnosis and treatment of latent TB is 
key to preventing active disease, but is hampered by limitations in ‘gold-standard’ diagnostic tests 
for determining true latent TB status5. Whilst prophylaxis with anti-TB medications is effective in 
preventing active disease, anti-TB medications are also associated with hepatitis, neurotoxicity and 
significant drug-drug interactions6-9. Screening patients for latent TB can be used to target 
prophylaxis to patients at highest risk of developing active TB, whilst avoiding unnecessary 
complications of treatment in low risk individuals.  
Until recently, the detection of latent TB has relied on the tuberculin skin test (TST). The utility of 
the TST in clinical practice is limited by poor sensitivity in immunocompromised people and poor 
specificity in Bacillus Calmette Guerin (BCG) vaccinated people10. An alternative to the TST are 
interferon gamma release assays (IGRAs), including the QuantiFERON®-TB Gold (QFT; Cellestis, 
www.cellestis.com) and T-SPOT®.TB (Oxford Immunotec, www.oxfordimmunotec.com). These 
tests are in-vitro T-cell based assays that measure the response of sensitized T-cells to 
mycobacterial antigens (early secretory antigenic target 6 [ESAT6] and culture filtrate protein 10 
[CFP10]) in whole blood. 
National guidelines for the diagnosis of latent TB are inconsistent11,12. Some guidelines offer no 
specific recommendation for test use13, some propose that IGRAs should be used following a 
negative TST14,15, whilst others recommend that IGRAs replace TST.  No specific guidelines exist 
for the ESKD population, however current recommendations from the United Kingdom indicate the 
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use of IGRAs with or without a TST in people with chronic kidney disease16. The few guidelines 
that exist for immunosuppressed populations (excluding HIV) are also conflicting. Canadian 
guidelines for immunosuppressed persons recommend using the TST with or without a 
supplementary IGRA14, whilst the United Kingdom and Switzerland recommend replacing the TST 
with an IGRA17,18. 
Determining the diagnostic accuracy of IGRAs in ESKD using epidemiological first principles is 
problematic because the existing standard test (TST) performs poorly and therefore makes direct 
comparison invalid. Previous systematic reviews of IGRA test performance are limited to the 
general population and most use two separate populations of people to estimate sensitivity (a 
population including only active TB cases) and specificity (a population of healthy low risk 
people)19-21. An alternative approach is to measure the association of test positivity with medical 
evidence of TB infection and epidemiological risk factors22. A pre-test clinical risk assessment 
encompassing a person’s risk of exposure, other co-morbidities and radiological imaging may help 
to interpret the validity of a positive or negative result. A test that is both sensitive and specific for 
latent TB should have test positivity closely associated with risk factors such as old TB on chest x-
ray, previous treatment for active TB, contact with an active case of TB, high risk nationality and 
immunosuppression (other than uraemic related). 
Given the paucity of evidence based guidance for clinical decision making, we aimed to 
systematically review all studies which assessed the association of TST or IGRA test results with 
clinical risk factors for latent TB in people with ESKD.
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Methods 
Inclusion/exclusion criteria 
We included all studies in any language that reported the performance of any diagnostic test for 
latent TB in conjunction with either medical evidence or clinical risk factors, in adults or children 
with ESKD. We excluded studies that included ESKD patients with active TB at the time of testing 
when data could not be separated from patients without active TB. 
Search strategy 
We searched MEDLINE and EMBASE from inception to October 2010. Articles were located 
using a search strategy composed of three filters, the first for test terms, the second for people with 
ESKD or CKD IV, and the third for TB terms. The full search strategy is available in 
Supplementary Table 1. We also searched conference proceedings, including: Australian Society for 
Microbiology 2005-10, Australian Society for Infectious Diseases 2007-10, Infectious Diseases 
Society of America 2007-10, Interscience Conference on Antimicrobial Agents and Chemotherapy 
2005-10, European Congress of Clinical Microbiology and Infectious Diseases 2005-10, American 
Society for Microbiology 2010 and International Congress on Infectious Diseases 2008-10.  The 
search was conducted by hand, or where electronic copies were available, we searched on the 
following text terms: tuberculosis, interferon, QuantiFERON, QFT, TSPOT.TB, ELISPOT, 
tuberculin skin test, TST, haemodialysis and hemodialysis.  
Data abstraction 
Data was abstracted from studies by three investigators working independently, using standardised 
data abstraction forms. We collected data on study setting and design, participant characteristics, 
risk factors for latent TB, test details and test results. We investigated both medical and 
epidemiological risk factors for latent TB (Supplementary Table 2). Medical risk factors included a 
8 
 
positive chest radiograph for past TB, previous active TB or prophylactic treatment for TB and any 
iatrogenic or disease related immunosuppression (other than uraemia related). Epidemiological risk 
factors included nationality and contact with a person with active TB (documented by a healthcare 
professional or self-reported). We also investigated BCG vaccination status as a protective factor. 
Study quality was assessed with an adapted version of the QUAlity assessment of Diagnostic 
Accuracy Studies (QUADAS) tool, see Supplementary Table 323. The QUADAS tool consists of 14 
methodological items which assess study validity in terms of appropriateness of patient spectrum 
and reference standard, bias, test execution, loss to follow up and indeterminate results. 
Statistical analysis 
The study setting, patient characteristics and the QUADAS tool data were summarised 
descriptively. Where sufficient data were available, we constructed 2x2 tables and calculated odds 
ratios (OR) (with 95% confidence intervals) for test positivity with each risk factor. When all 
patients in a study had a risk factor, or all patients with a risk factor had the same result, we added 
0.5 to each cell of the 2x2 table to calculate the OR24. In studies that assessed two or more tests in 
the same population, we compared the association of test positivity with risk factor between tests as 
a relative diagnostic odds ratio (ROR, with 95% confidence intervals). Variance was calculated 
using a previously published method which assumes a correlation between tests of 0.5, producing 
conservative estimates22. Statistical significance was tested with a Wald test and reported as a p-
value. Forest plots and summary estimates for ORs and RORs were generated in STATA 11.2 
(Statacorp, USA) using a random effects model weighted by inverse variance. Heterogeneity 
between was assessed using the I2 statistic, which reports the percentage of variation across studies 
that is due to true heterogeneity rather than chance. 
 
Sensitivity analysis 
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To test the robustness of our results against inter-study heterogeneity, we conducted sensitivity 
analyses using random effects meta-regression. Specifically, we compared studies of dialysis 
patients alone versus transplant/mixed populations of dialysis and transplant patients, studies that 
used blinding of test interpretation to other test results versus those that did not use blinded 
interpretation, studies that used a TST cut-off of 5mm versus 10mm and studies that used second 
generation versus third generation QFT tests. 
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Results 
Our search identified 949 potential citations. Nine hundred and thirty seven citations where 
identified in electronic databases, nine citations where identified in conference proceedings, one 
citation came from reference list searches and one citation came from an expert in the field (Figure 
1).  In total 47 studies (6828 participants) were included, however only 30 studies (4546 
participants) contained sufficient data to contribute to meta-analysis.  
The characteristics of included studies that contributed to meta-analysis are listed in Table 1. In 
general, studies were mostly conducted in dialysis patients (23/30 [76.7%]) and in countries with 
low (≤ 5 cases/100000) to moderate (≤ 50 cases/100000) TB prevalence25. The study setting was 
primarily outpatient dialysis clinics and all studies were prospective. Two studies (306 participants) 
were conducted as contact investigations in response to possible TB exposure26,27. Seventeen 
studies (2903 participants) evaluated TST only, nine studies (1126 participants) directly compared 
an IGRA with TST, and the remaining four studies (517 participants) evaluated flow cytometry or 
antibody detection kits. 
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Table 1: Characteristics of included studies 
Study Test evaluation Country N Males (%) Age (years ± SD) 
ESKD treatment 
(months ± SD) 
BCG vaccinated 
(%) 
TB prevalence† 
case/105 persons (95% CI) 
Dialysis population 
Inoue 200928 TST vs QFT Japan 154 97 (59.9) 65.4 ± 65 42.4 ± n/s n/s‡ 74.6 (8.3-46.0) 
Lee 201029,30 TST vs QFT Taiwan 93 35 (37.6) 58.3 ± 14.9 72.0 61.3 137.0 (56.0-225.0)* 
Seyhan 201031 TST vs QFT Turkey 100 47 (47.0) 56.2 ± 15.3 n/s 67.0 41.0 (15.0-71.0) 
Kim 201032,33 TST vs TSPOT.TB South Korea 209 78 (72.2) n/s n/s n/s 115.0 (38.0-197.0) 
Chung 201034 TST vs QFT vs TSPOT.TB South Korea 167 71 (42.5) 54.1 ± 14.4 60.8 ± 57.5 66.5 115.0 (38.0-197.0) 
Triverio 200935 TST vs QFT vs TSPOT.TB Switzerland 62 46 (74.2) 65.0 ± 15.0 n/s 22.6 5.7 (1.9-9.8) 
Lee 200936,37 TST vs QFT vs TSPOT.TB Taiwan 32 34 (54.8) 54.9 ± 10.1 n/s 71.9 137.0 (56.0-225.0)* 
Eleftheriadis 200538 TST vs Antibody detection Greece 95 53 (55.8) n/s n/s 100.0 8.3 (2.8-14.0) 
Yanai 200639 TST vs Antibody detection Japan 243 148 (60.9) 60.0 ± 11.0 86.0 ± 84.0 n/s 29.0 (9.2-49.0) 
Wauters 200440 TST Belgium 224 130 (58.0) n/s n/s 2.7 15.0 (5.0-25.0) 
Shankar 200541 TST India 108 78 (72.2) 37.75 ± 11.8 51.6 ± 31.2 70.4 258.0 (114.0-431.0) 
Fang 200242 TST Taiwan 177 78 (44.1) 54.7 ± 17.3 40.0 ± 28.9 48.0 214.0 (99.0-315.0)* 
Yildiz 199843,44 TST Turkey 29 17 (58.6) 30.9 ± 9.5 20.5 ± 17.4 n/s 75.0 (32.0-125.0) 
Ates 201045,46 TST Turkey 779 381 (48.9) 51.2 ± 15.9 35.1 ± 33.4 53.9 41.0 (15.0-71.0) 
Habesoglu 200747 TST Turkey 187 97 (51.9) 50.0 ± 15.9 53.1 ± 54.9 55.1 42.0 (14.0-73.0) 
Taskapan 200048 TST Turkey 30 17 (56.7) 42.0 ± 12.0 27.8 ± 15.9 60.0 75.0 (32.0-125.0) 
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Dogan 200549 TST Turkey 124 56 (45.2) 45.3 ± 16.2 30.0 ± 17.0 90.3 46.0 (16.0-80.0) 
Cengiz 200650 TST Turkey 106 47 (44.3) 49.9 ± 14.4 107.0 ± 54.8 100.0 42.0 (14.0-74.0) 
Woeltje 199851 TST USA 307 129 (42.0) 58 3.7 0.0 7.9 (2.6-13.0) 
Smirnoff 199852 TST USA 50 28 (56.0) 55 44.4 16.0 7.9 (2.6-13.0) 
Hickstein 200727 TST USA 212 n/s n/s n/s n/s 6.0 (2.1-10.0) 
Linquist 200226 TST USA 94 n/s n/s n/s n/s 7.9 (2.6-13.0) 
Poduval 200353 TST USA 118 59 (50.0) n/s n/s n/s 6.5 (2.2-11.0) 
Transplant population 
Sester 200654 TST vs Flow cytometry Germany 117 n/s 53.1 ± 14.8 n/s n/s 8.8 (2.9-15.0) 
Sester 200955 Flow cytometry Germany 62 34 (54.8) n/s n/s n/s 6.2 (2.0-11.0) 
Mixed dialysis and transplant population 
Passalent 200756 TST vs TSPOT.TB Canada 209 78 (44.1) n/s n/s 78.0 6.1 (2.2-11.0) 
Winthrop 200857 TST vs QFT vs TSPOT.TB USA 100 130 (58.0) n/s n/s n/s 4.7 (1.3-8.0) 
Kantarci 200658 TST Turkey 164 86 (52.4) 35.2 ± 10 43.0 ± 32 14.6  
Aydogan 200959 TST Turkey 150 72 (48.0) 48.1 ± 16.7 n/s 62.0 41.0 (15.0-71.0) 
Basoglu 200660 TST Turkey 44 25 (56.8) 46.6 ± 15.6 n/s 90.9 42.0 (14.0-71.0) 
†National prevalence of TB in in year of study publication, *TB prevalence in Taiwan estimated from data for China, ‡Not specified
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The characteristics of included studies that did not provide sufficient data to contribute to meta-
analysis are listed in Supplementary Table 4. Six studies directly compared the TST and an IGRA, 
seven studies evaluated TST only, three studies evaluated QFT only and one study evaluated flow 
cytometry.  These studies included 2282 participants, of which 1258 were on dialysis, 820 were 
transplanted, and the remaining 204 were not specified. Age and time spent on treatment of 
participants was similar between studies that contributed to meta-analysis and those that did not.  
Data on BCG vaccination rate was limited. 
Results of the study quality assessment are presented in Figure 2. Overall, the quality of studies 
included in the review was suboptimal and often insufficient detail was available to make a 
judgment about potential bias.  The method of patient recruitment was unclear in most studies 
(46/47 [97.8%]). The blinding of test interpretation to other test results and to knowledge of clinical 
risk factors was also predominately unclear (20/47 [42.6%] and 45/48 [95.7%] respectively). Risk 
factor assessment and test procedures were generally described in sufficient detail to repeat the 
studies (30/47 [63.8%] and 41/47 [87.2%] respectively). The clinical risk assessment was 
considered comprehensive in 37/47 studies (78.7%). Few studies reported unexplainable 
indeterminate results or participant withdrawals. Study quality was poor but not different across 
studies that contributed to meta-analysis and those that did not; see Supplementary Figure 1 for 
quality assessment of only studies that contributed to meta-analysis. 
Association of test positivity with clinical risk factors 
Overall, positive tests for latent TB as measured by QFT, TSPOT.TB and TST were significantly 
associated with a medical history of TB infection (QFT; OR 6.01 [95%CI 2.66-13.56, p=0.001], 
TSPOT.TB; OR 5.02 [95%CI 2.13-11.87, p=0.001], TST; OR 1.95 [95%CI 1.17-3.23, p=0.01]). A 
positive QFT test was strongly associated with radiological evidence of TB infection (OR 2.97 
[95%CI 1.30-6.82, p=0.01]) and contact with a case of active TB (OR 3.52 [95%CI 1.69-7.31, 
p=0.001]). In contrast, there was insufficient evidence to determine the direction of association of a 
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positive TST with radiological evidence of TB infection (OR 0.79 [95%CI 0.9-3.25, p=0.7]) or 
contact with (OR 0.88 [95%CI 0.43-1.82, p=0.7]). The direction of association of a positive 
TSPOT.TB with radiological evidence of TB infection and contact with a case of active TB was 
also unclear (OR 1.88 [95%CI 0.43-8.22. p=0.4] and OR 1.42 [95%CI 0.80-2.52, p=0.2] 
respectively). There was insufficient evidence to determine the direction of association of test 
positivity with high-risk nationality, immunosuppression and BCG vaccination for all tests, see 
Supplementary Figures 2-7. Comparing studies that blinded test interpretation to information about 
clinical risk factors to those that did not or were unclear, we found no significant differences in 
association of test positivity for radiological evidence of TB, medical evidence of TB, contact with 
active TB, immunosuppression or nationality (p>0.5). The OR for the association of TST positivity 
with BCG vaccination was significantly higher in unblinded studies (2.04 [95%CI 1.18-3.53]) 
compared to blinded studies (0.63 [95%CI 0.27-1.46]), p=0.05. A significant difference was also 
found in the association of a positive TST with immunosuppression when studies were stratified by 
modality of ESKD treatment. The summary OR was higher in studies of dialysis patients (OR 1.38 
[95%CI 0.98-1.94]) than transplant and mixed populations (OR 0.38 [95%CI 0.22-0.67]), p=0.004. 
There were no significant differences for other risk factors when studies were stratified by modality 
of ESKD treatment (p>0.1). Our findings also remained unchanged when we compared studies 
using a TST cut-off of 5mm versus 10mm (p>0.1) and studies that used second versus third 
generation QFT tests (p>0.4). 
Relative association of QFT, TSPOT.TB and TST test positivity with clinical risk factors 
Figures 3-5 show the direct comparison between IGRAs and TST for association of test positivity 
with clinical risk factors. From the findings of six studies, compared to a positive TST, a positive 
QFT test was more strongly associated with radiological evidence of past TB (ROR 4.29 [95%CI 
1.83-10.03, p=0.001]) and contact history with active TB (ROR 3.36 [95%CI 1.61-7.01, p=0.001]) 
(Figure 3). Conversely, a positive QFT test was less strongly associated with BCG vaccination 
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compared to a positive TST (ROR 0.30 [95%CI 0.14-0.63, p=0.002]) (Figure 3). There was no 
evidence of a difference of association of test positivity with high-risk nationality (ROR 2.25 
[95%CI 0.53-9.61, p=0.3]) or medical history of TB (ROR 2.68 [95%CI 0.97-7.43, p=0.06]) 
between the QFT and TST. Data from six studies comparing the performance of the TSPOT.TB and 
TST tests showed there was no evidence of a difference between the association of a positive 
TSPOT.TB or TST result for any of the risk factors (Figure 4).  
Four studies compared the QFT and TSPOT.TB tests directly. One study reported a positive 
TSPOT.TB to be more strongly associated with radiological evidence of past TB than a positive 
QFT (ROR 0.11 [95%CI 0.02-0.77, p=0.03]). No evidence of a difference was found for any of the 
other risk factors, see Figure 5. These results were robust to heterogeneity in TST cut-off (p>0.3), 
QFT test generation (p>0.5) and modality of ESKD treatment (p>0.3).  
Comparisons of other tests for latent TB 
Two studies evaluated flow cytometry, one evaluated both ESAT-6 and TuberkulinGT-100 as 
stimulating antigens and the other evaluated only ESAT-638,39. All transplant recipients were 
assumed to be immunosuppressed. There was no significant association between flow cytometry 
positivity (using TuberkulinGT-100 or ESAT-6 as the stimulating agent) and immunosuppression 
(OR 1.36 [95%CI 0.08-22.13, p=0.8] and OR 0.43 [95%CI 0.01-22.46, p=0.7] respectively), see 
Supplementary Figure 6. In one study TST was also evaluated, however no difference in association 
with immunosuppression was found between flow cytometry (using either ESAT-6 or 
TuberkulinGT-100) and TST (ROR 4.58 [95%CI 0.09-244.796, p=0.5] and ROR 1.80 [95%CI 
0.033-98.112, p=0.8] respectively). Two studies evaluated antibody detection kits. In one study 
both the Mycodot and Determiner test positivity were significantly associated with radiological 
evidence of past TB (OR 3.47 [95%CI 1.33-9.07, p=0.01] and OR 2.18 [95%CI 1.04-4.59, p=0.04] 
respectively). The other study, which evaluated Mycodot only, showed no significant association of 
test positivity with BCG vaccination (OR 0.44 [95%CI 0.01-22.61, p=0.7]).  
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Discussion 
Screening for latent TB in the ESKD population allows treatment to be targeted at persons with the 
highest risk of active TB and who will benefit most from prophylaxis. The key finding of this 
review is that compared to the TST, QFT test positivity was more strongly associated with clinical 
risk factors for latent TB, whilst less strongly associated with prior BCG vaccination. This suggests 
that QFT is both more sensitive and specific than the TST in the context of ESKD. Global 
guidelines for latent TB screening in immunocompromised populations currently recommend using 
an IGRA as a supplementary or replacement test to the TST11. The results of this review support the 
replacement of the TST with the QFT. Not enough data was available on the relative performance 
of TSPOT.TB with the TST, or TSPOT.TB with QFT to make any conclusions about the 
TSPOT.TB test.  
The data analysed in the present study was largely restricted to the dialysis population (3700/4546 
[81.4%]). Whilst this may be considered a limitation, the performance of tests for latent TB in the 
dialysis population is most clinically relevant because assessment for latent TB generally occurs 
prior to commencing dialysis or during clinical evaluation leading up to kidney transplantation61.  
Compared to both the TST and TSPOT.TB tests the QFT assay demonstrated the strongest overall 
association with clinical risk for latent TB, including radiological evidence of past TB (OR 2.97, 
Supplementary Figure 2, medical evidence of past TB (OR 6.01, Supplementary Figure 3) and 
contact with a person with active TB (OR 3.52, Supplementary Figure 4). Data was less conclusive 
for the utility of the TSPOT.TB test, although positive results from this assay were associated with 
a medical evidence of past TB (OR 5.02, Supplementary Figure 3). We found no association 
between nationality and test positivity for any of the tests, however in these analyses data was 
limited to studies conducted in countries with low to moderate TB burden. The clinical value of 
IGRAs for detecting latent TB in different patient populations in high prevalence regions warrants 
study. 
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Studies that met the inclusion criteria but did not provide sufficient data to contribute to meta-
analysis represent a potential source of bias in this review. These studies accounted for 36.2% 
(17/47) of included studies and 33.4% (2282/6828) of all participants. Due to missing data on study 
design and patient characteristics it was not possible to formally compare differences between 
studies that contributed to meta-analysis and those that did not, see Table 1 and Supplementary 
Table 4. The available data suggest that patient characteristics within the dialysis and transplant 
populations are similar between studies that contributed to meta-analysis and those that did not, but 
there appear to be proportionately more transplant recipients in the studies that did not contribute to 
meta-analysis.   
Another key finding of the present study is that based on best available evidence, the preferred 
IGRA for diagnosing latent TB is the QFT assay, even though comparison of either the QFT or 
TSPOT-TB assays with the TST and each other was limited by the small number of evaluable 
studies (n=<10 for each comparison; Figure 3-5). Data from six studies indicate that compared to 
the TST, QFT positivity was more strongly associated with clinical risk factors for latent TB, whilst 
comparing TSPOT.TB and TST no statistical differences were observed in ROR for any clinical 
risk factors 32,34-36,56,57. Only a single study out of four comparing the performance of TSPOT.TB 
and QFT in ESKD showed that the former was more strongly associated with radiological evidence 
of past TB than the QFT assay35.  
Although the utility of assays other than the QFT, TST and TSPOT.TB have been studied in the 
context of diagnosing of latent TB, neither serological detection of antibody to M. tuberculosis or 
flow cytometry studies have been shown to be clinically useful and sensitivity analyses have been 
limited by the small number of reports10,38,39,54,55. Based on present available data, these assays 
cannot be recommended for assisting in the diagnosis of latent TB.  
Systematic reviews are the preferred format for summarising evidence because they use explicit and 
reproducible methods to limit bias. We acknowledge that the validation of test results against 
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clinical risk factors has several limitations. Whilst this approach allows us to make inferences about 
the accuracy of tests in relative terms, it does not allow us to calculate absolute measures of test 
accuracy. To derive test accuracy characteristics, previous reviews in the general population have 
overcome the lack of a reference standard by using active TB and low risk individuals as surrogates 
for positive and negative latent TB status19-21. This method is dubious because active and latent TB 
are distinct disease states that elicit different responses from the host immune system and therefore 
it may be inappropriate to use active TB as an immunological model for latent TB1,62. Several 
studies have shown that responses to the TST and IGRAs diminish during untreated active TB 
infection, but rapidly increase after treatment, suggesting active TB may suppress the host immune 
response to these tests63-66. 
Another limitation of this review is that the implications of our results rely on the assumption that a 
high proportion of people with clinical risk factors for latent TB actually have latent TB. Although 
this assumption is difficult to prove, given the lack of a reference standard for latent TB, there is 
evidence that active TB is more likely to develop in dialysis patients with old TB on chest X-ray or 
immunosuppressive diseases including diabetes mellitus and HIV infection67. Risk factors for the 
transmission of latent TB may also be inaccurate and difficult to quantify and therefore a potential 
source of heterogeneity between studies22. For example, the studies included in this review assessed 
contact with active TB as a dichotomous risk factor only, whereas from epidemiological studies we 
know that the likelihood of transmission is determined by both time and proximity to a person with 
active TB22. Assessing nationality as a dichotomous risk factor is similarly problematic, because it 
assumes that all individuals from a country with high TB burden have the same risk of transmission, 
whereas in reality transmission requires and interplay of several factors, including socioeconomic 
status, time spent in the country and where that time was spent in the country. 
Future research in this area should pursue three directions. Firstly, this review demonstrated a gap 
in evidence on the relative test performance of the QFT and TSPOT.TB. More studies are required 
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to assess the relative performance of these tests in the ESKD population. Secondly, a study 
assessing the active TB rate in patients after test directed treatment would be helpful to derive the 
relative clinical value of the TST, QFT and TSPOT.TB. Thirdly, a cost-effectiveness evaluation is 
needed to determine whether the reduction in false positive and negative results that occurs when 
QFT replaces the TST is worth the trade-off in any cost increase that may also occur.  
In conclusion, we determined that compared to the TST, the QFT positivity was more strongly 
associated with risk factors for latent TB in ESKD and is therefore likely to be a more accurate 
diagnostic tool for latent TB in ESKD. This finding is consistent with previous systematic reviews 
conducted in the general population which showed that IGRA results correlate better with the 
intensity of TB exposure compared to the TST whilst remaining independent of BCG vaccination 
status22, and that IGRAs are more sensitive and specific and thus the preferred tests19-21. On the 
basis of best available evidence, we propose that the QFT assay should be the test of choice for 
screening for latent TB, and a review clinical practice guidelines for managing latent TB in the 
ESKD population is warranted. 
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Figure 1: Results of literature search for studies reporting test performance and risk factor 
assessment for latent TB in people with end stage kidney disease  
*TST = Tuberculin skin test, QFT = QuantiFERON 
†See Supplementary Table 4 for study details 
 
Figure 2: Methodological quality of studies included in review 
QUADAS 1: Generalisability of test results to ESKD population (spectrum bias), QUADAS 2: 
Participant selection method adequate (selection bias), QUADAS 3: Comprehensive risk factor 
assessment (verification bias), QUADAS 4: Acceptable delay between testing and risk factor 
assessment (disease progression bias), QUADAS 5: All patients had all tests (partial verification 
bias), QUADAS 6: All patients had the same tests (differential verification bias), QUADAS 7: Risk 
factor assessment independent from tests (incorporation bias), QUADAS 8: Tests described in 
sufficient detail to repeat (repeatability), QUADAS 9:  Risk factor assessment described in 
sufficient detail to repeat (repeatability), QUADAS 10: Tests interpretation conducted without 
knowledge other test results(blinding), QUADAS 11: Risk factor assessment conducted without 
knowledge of test results (blinding), QUADAS 12: Normal clinical information available during 
risk factor assessment and test interpretation (information bias), QUADAS 13: Reasons for 
indeterminate results provided, QUADAS 14: Reasons for withdrawals provided (intention to treat 
bias), * See supplementary figure 1 for quality of studies contributing to meta-analysis 
 
Figure 3: TST versus QFT:  relative association of a positive test with risk factors for latent 
TB  
 
Figure 4: TST versus TSPOT.TB: relative association of a positive test with risk factors for 
latent TB  
 
Figure 5: TSPOT.TB versus QFT: relative association of a positive test with risk factors for 
latent TB
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Supplementary figure 1: Methodological quality of studies contributing to meta-analysis 
White: Low risk (good quality), Black: high risk (poor quality): Grey: unclear, QUADAS 1: 
Generalisability of test results to ESKD population (spectrum bias), QUADAS 2: Participant 
selection method adequate (selection bias), QUADAS 3: Comprehensive risk factor assessment 
(verification bias), QUADAS 4: Acceptable delay between testing and risk factor assessment 
(disease progression bias), QUADAS 5: All patients had all tests (partial verification bias), 
QUADAS 6: All patients had the same tests (differential verification bias), QUADAS 7: Risk factor 
assessment independent from tests (incorporation bias), QUADAS 8: Tests described in sufficient 
detail to repeat (repeatability), QUADAS 9:  Risk factor assessment described in sufficient detail to 
repeat (repeatability), QUADAS 10: Tests interpretation conducted without knowledge other test 
results(blinding), QUADAS 11: Risk factor assessment conducted without knowledge of test results 
(blinding), QUADAS 12: Normal clinical information available during risk factor assessment and 
test interpretation (information bias), QUADAS 13: Reasons for indeterminate results provided, 
QUADAS 14: Reasons for withdrawals provided (intention to treat bias) 
 
Supplementary figure 2: Association of test positivity with radiological evidence of past TB 
 
Supplementary figure 3: Association of test positivity with medical evidence of past TB 
 
Supplementary figure 4: Association of test positivity with active TB contact 
 
Supplementary figure 5: Association of test positivity with BCG vaccination 
 
Supplementary figure 6: Association of test positivity with immunosuppression  
 
Supplementary figure 7: Association of test positivity with high-risk nationality 
 
Supplementary table 1: Electronic search strategy for MEDLINE and EMBASE (06/10/2010) 
 
Supplementary table 2: Standard definitions of risk factors 
 
Supplementary table 3: QUADAS working definitions   
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